Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan sucrosofate - Ipsen

Next Previous
Drug Profile

Irinotecan sucrosofate - Ipsen

Alternative Names: BAX-2398; Irinotecan liposome injection - Merrimack; Liposomal irinotecan - Ipsen/Servier; MM-398; nal-IRI; Nano-irinotecan; Nanoliposomal irinotecan - Merrimack/PharmaEngine; Nanoliposomal irinotecan injection - Merrimack/PharmaEngine; Onivyde; pegylated liposomal irinotecan hydrochloride trihydrate; PEP-02; S-095013; SHP-673

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Academic Medical Center; HERMES BioSciences
  • Developer Academic Medical Center; AIO Studien gGmbH; Bristol-Myers Squibb; Emory University; Federation Francophone de Cancerologie Digestive; Ipsen; Medica Scientia Innovation Research; Merrimack Pharmaceuticals; National Cancer Institute (USA); PharmaEngine; Rhode Island Hospital; Servier; Shire; Taiho Pharmaceutical; University of California at San Francisco; University of Florida; University of Michigan
  • Class Alcohols; Alkaloids; Alkanes; Antineoplastics; Camptothecins; Esters; Indolizines; Ketones; Piperidines; Pyrans; Quinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase III Small cell lung cancer
  • Phase II Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; HER2 negative breast cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer
  • Phase I/II Gastrointestinal cancer; Glioblastoma
  • No development reported Glioma; Solid tumours

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (IV, Infusion)
  • 10 Jan 2025 Federation Francophone de Cancerologie Digestive completes phase II FUNGEMAX trial for Pancreatic cancer (Combination therapy, Metastatic disease) in France (IV)(NCT03693677) (EudraCT2017-004309-41)
  • 15 Nov 2024 University of Michigan Rogel Cancer center completes a phase I/II trial in Biliary cancer (Combination therapy, second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT03785873)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top